8-K: Pediatrix Reports Strong Q4, Exceeds Expectations

Pediatrix Medical Group announced fourth-quarter and full-year 2025 results, reporting Adjusted EPS of $0.50 for Q4 and providing a preliminary 2026 Adjusted EBITDA outlook.

Summary

• Net revenue for the three months ended December 31, 2025, was $493.8 million, compared to $502.4 million for the prior-year period, reflecting practice dispositions partially offset by 4.0% same-unit net revenue growth.
• Net income for the 2025 fourth quarter was $33.7 million, or $0.40 per diluted share, an increase from $30.5 million, or $0.36 per diluted share, in the 2024 fourth quarter.
• Adjusted EPS for the 2025 fourth quarter was $0.50, slightly down from $0.51 in the 2024 fourth quarter.
• Adjusted EBITDA for the 2025 fourth quarter was $65.8 million, compared to $68.7 million for the prior-year period, primarily due to higher same-unit expense.
• For the full year ended December 31, 2025, net revenue was $1.91 billion, compared to $2.01 billion for the prior year.
• Full year 2025 net income was $165.4 million, or $1.94 per share, a significant improvement from a net loss of $99.1 million, or $1.19 per share, in 2024.
• Full year 2025 Adjusted EBITDA increased to $275.6 million from $224.0 million in 2024.
• Full year 2025 Adjusted EPS was $2.04, up from $1.51 in 2024.
• Cash and cash equivalents stood at $375.2 million at December 31, 2025, an increase from $229.9 million at December 31, 2024.
• Total debt outstanding was $597 million at December 31, 2025, with no outstanding borrowings under the $450 million revolving line of credit.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, reflecting a strong turnaround in full-year profitability and effective management of operational challenges, despite some Q4 revenue and EBITDA dips due to strategic dispositions and compensation increases.

Positives

• Fourth quarter operating results were in line with revised upward expectations.
• Achieved solid same-unit revenue growth of 4.0% in Q4 2025.
• Same-unit revenue from net reimbursement-related factors increased by 6.7% due to improved collection activity, favorable payor mix, higher patient acuity, and increased administrative fees.
• Net income increased to $33.7 million in Q4 2025 from $30.5 million in Q4 2024.
• Full year 2025 net income of $165.4 million represents a significant turnaround from a $99.1 million net loss in 2024.
• Full year 2025 Adjusted EBITDA increased substantially to $275.6 million from $224.0 million in 2024.
• Full year 2025 Adjusted EPS increased to $2.04 from $1.51 in 2024.
• Cash and cash equivalents significantly increased to $375.2 million at year-end 2025 from $229.9 million in 2024.
• No outstanding borrowings under the $450 million revolving line of credit, indicating strong liquidity.
• Transformational and restructuring related expenses decreased significantly to $5.9 million in Q4 2025 from $23.6 million in Q4 2024.
• Share repurchase activity during 2025 contributed to a decrease in weighted average shares outstanding.

Negatives

• Net revenue decreased to $493.8 million in Q4 2025 from $502.4 million in Q4 2024, primarily due to practice dispositions.
• Adjusted EBITDA decreased to $65.8 million in Q4 2025 from $68.7 million in Q4 2024, primarily due to higher same-unit expense, including variable practice incentive compensation.
• Same-unit patient service volumes decreased by 2.7% for the 2025 fourth quarter.
• Hospital-based patient services volumes decreased by 3.3% in Q4 2025.
• Office-based patient services volumes decreased by 2.3% in Q4 2025.
• Neonatal intensive care unit (NICU) days decreased by 2.0% in Q4 2025.
• Cash from operating activities from continuing operations decreased to $114.6 million in Q4 2025 from $134.8 million in Q4 2024.

Risks

• The impact of practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom.
• The effects of economic conditions on the Company's business.
• The effects of the Medicare Access and CHIP Reauthorization Act of 2015, the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform.
• The Company's relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors.
• The impact of state budgetary constraints and uncertainty over the future of Medicaid.
• The impact of surprise billing legislation.
• The Company's transition to a hybrid revenue cycle management model.
• The timing and contribution of future acquisitions or organic growth initiatives.
• The Company's ability to comply with the terms of debt financing arrangements.
• The effects of the Company's transformation initiatives, including renewed focus, and growth strategy for, the Company's hospital-based and maternal fetal businesses.

Future Outlook

Pediatrix anticipates its 2026 Adjusted EBITDA to be in a preliminary range of $280 million to $300 million.

Management Comments

• Our fourth quarter operating results were in line with our revised upward expectations and reflected solid same-unit revenue growth, partially offset by an increase in variable practice incentive compensation.
• Our performance in the fourth quarter caps a terrific year, and while facing healthcare industry headwinds, we are doing all we can to have another strong year at Pediatrix and to position ourselves for a strong future.

Industry Context

StockSavvy.ai notes that Pediatrix's focus on improving collection activity, favorable payor mix, and higher patient acuity in hospital-based practices, particularly neonatology, demonstrates a strategic response to the broader healthcare industry headwinds mentioned by management. The decrease in overall revenue due to practice dispositions, while impacting top-line growth, aligns with a trend of companies optimizing their portfolio for profitability and efficiency in a challenging environment. The significant turnaround from a net loss in 2024 to a substantial net income in 2025 suggests effective cost management and operational improvements, potentially outperforming some peers struggling with similar pressures.

Stakeholder Impact

• Shareholders: Positive impact due to increased net income, strong Adjusted EBITDA growth for the full year, share repurchase activity, and a positive 2026 Adjusted EBITDA outlook.
• Employees: Potential impact from 'position eliminations' mentioned in transformational and restructuring expenses, though these expenses significantly decreased. Increased variable practice incentive compensation for clinicians.
• Customers (Patients): Continued provision of coordinated, compassionate, and clinically excellent services. Higher patient acuity in hospital-based practices suggests continued demand for specialized care.
• Hospital Partners: Increased administrative fees from hospital partners indicate strong relationships and value provided.
• Creditors: Total debt outstanding of $597 million is manageable, with no outstanding borrowings on the revolving credit line, indicating good liquidity.

Next Steps

• Host an investor conference call on February 19, 2026, at 9 a.m. ET to discuss the quarterly results.
• Continue efforts to have another strong year in 2026 and position the company for a strong future.

Key Dates

Recommendation

The company demonstrated a significant financial turnaround in 2025, moving from a net loss to substantial net income and showing strong Adjusted EBITDA growth. Despite a slight dip in Q4 Adjusted EBITDA due to strategic dispositions and increased variable compensation, the overall trajectory is positive, with management meeting revised upward expectations. The strong cash position and lack of revolving credit debt indicate financial health. The 2026 Adjusted EBITDA guidance suggests continued growth. These factors, combined with strategic portfolio management and improved reimbursement, make Pediatrix an attractive investment for growth-oriented portfolios.

Keywords

Pediatrix Medical Group, MD, physician services, neonatology, maternal-fetal medicine, obstetrics, pediatric subspecialties, healthcare, financial results, earnings, Adjusted EBITDA, EPS, revenue cycle management, hospital-based services, Q4 2025, 2025 full year